Background Dehydroepiandrosterone (DHEA) is helpful for treating vaginal symptoms. This secondary analysis evaluated the impact of vaginal DHEA on hormone concentrations, bone turnover, and vaginal cytology in women with a cancer history. Methods Postmenopausal women, diagnosed with breast or gynecologic cancer, were eligible if they reported at least moderate vaginal symptoms. Participants could be on tamoxifen or aromatase inhibitors (AIs). Women were randomized to 3.25 versus 6.5 mg/day of DHEA versus a plain moisturizer (PM) control. Sex steroid hormone levels, biomarkers of bone formation, vaginal pH, and maturation index were collected at baseline and 12 weeks. Analysis included independent t tests and Wilcoxon rank tests, comparing each DHEA arm with the control.
Abstract
Background Dehydroepiandrosterone (DHEA) is helpful for treating vaginal symptoms. This secondary analysis evaluated the impact of vaginal DHEA on hormone concentrations, bone turnover, and vaginal cytology in women with a cancer history. Methods Postmenopausal women, diagnosed with breast or gynecologic cancer, were eligible if they reported at least moderate vaginal symptoms. Participants could be on tamoxifen or aromatase inhibitors (AIs). Women were randomized to 3.25 versus 6.5 mg/day of DHEA versus a plain moisturizer (PM) control. Sex steroid hormone levels, biomarkers of bone formation, vaginal pH, and maturation index were collected at baseline and 12 weeks. Analysis included independent t tests and Wilcoxon rank tests, comparing each DHEA arm with the control.
Results Three hundred forty-five women contributed evaluable blood and 46 contributed evaluable cytology and pH values. Circulating DHEA-S and testosterone levels were significantly increased in those on vaginal DHEA in a dosedependent manner compared to PM. Estradiol was significantly increased in those on 6.5 mg/day DHEA but not in those on 3.25 mg/day DHEA (p < 0.05 and p = 0.05, respectively), and not in those on AIs. Biomarkers of bone formation were unchanged in all arms. Maturation of vaginal cells was 100% (3.25 mg/day), 86% (6.5 mg/day), and 64% (PM); pH decreased more in DHEA arms. Conclusion DHEA resulted in increased hormone concentrations, though still in the lowest half or quartile of the postmenopausal range, and provided more favorable effects on vaginal cytology, compared to PM. Estrogen concentrations in women on AIs were not changed. Further research on the benefit of vaginal DHEA is warranted in hormone-dependent cancers.
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Background
Menopause results in reduced concentrations of circulating estradiol in the female body and can be accompanied by many symptoms, such as vaginal dryness and dyspareunia [1, 2] . Treatment for hormone-sensitive breast cancer often seeks to largely deplete estradiol concentrations, sometimes by blocking aromatase, an enzyme necessary for estrogen conversion. This treatment can add to the extent and severity of menopausal symptoms, particularly vaginal symptoms such as dryness and dyspareunia [3, 4] . Vaginal symptoms due to estrogen deprivation do not spontaneously resolve, in contrast to hot flashes, as there is a cumulative detrimental effect on the vaginal tissues over time [2, 5] .
The relationship between estrogen deprivation and worsening vaginal symptoms over time is due to the major role that estrogen and estrogen receptors play in vaginal architecture [6, 7] . The vaginal wall contains squamous epithelium, a lamina propria, a smooth muscle layer, and a covering membrane, all of which are influenced by estrogen. The role of estradiol is multi-faceted and includes maintaining the fluid film that lines the vaginal walls, keeping the epithelium dense with more mature cells, keeping vaginal smooth muscle functional, and contributing to tissue elasticity [6] . Additionally, estrogen is responsible for vasodilatation in the lamina propria and promotes the expression of various neurotransmitters that ultimately result in increased blood flow [6, 7] .
Without estrogen, the vagina undergoes changes that can negatively impact sexual function and satisfaction. The more mature epithelial cells decrease while less mature parabasal cells become the major cytology. Collagen, blood flow, and lubrication decrease, resulting in an inflexible network of dry cells with a higher pH; this leads to an increased susceptibility to infection and itching, and an uncomfortable sensation of dryness [8] . The smooth muscle becomes less functional, challenging orgasm. Intercourse can become painful, with friable tissues subject to bleeding and trauma. Upon visual inspection, an atrophic vagina appears thin and pale, with a parched epithelium. The vagina appears shorter, with a loss of rugae and elasticity and decreased secretions [8, 9] .
Based on the important role of estrogen in the vagina, the gold standard treatment for vaginal symptoms has been localized estrogen [10] . However, vaginal estrogen may not be a desirable option for some women, including women who are concerned about cancer risk and those with estrogen-sensitive tumors. Even low doses of vaginal estrogen have resulted in significant increases in systemic concentrations [11] [12] [13] or effects outside of the vagina; after 6-12 months of 7.5 mcg of vaginal estrogen, there are improvements in lipid profiles [14] and/or reductions in biomarkers of bone turnover [15] . These "off-target," outside-of-the-vagina effects (such as effects on lipids, bones) may occur in the absence of detectable or clinically important increases in serum concentrations and are a theoretical risk for women with hormone-sensitive cancer as estrogen can bind to receptors in any tissue, including the breast [14, 15] . Consequently, effective treatments for vaginal symptoms that do not result in estrogenic systemic activity would be a welcome option for many women, particularly those on aromatase inhibitors, as safe levels of estradiol concentration increases have not been established [16] .
Dehydroepiandrosterone (DHEA) is a vaginal treatment that has been studied in over 500 postmenopausal women [17] [18] [19] ; it is believed to act locally to improve symptoms, without influencing systemic physiology [20] . DHEA is made by the adrenal gland and decreases with aging, not specifically with menopause. After menopause, DHEA is a major source of sex steroid hormones [21] . The Food and Drug Administration recently approved a DHEA ovule for the treatment of dyspareunia in postmenopausal women with the genitourinary syndrome of menopause. The ovule, or any other type of vaginal DHEA, had not previously been studied in women with a history of breast or gynecologic cancer.
The purpose of this paper is to report secondary physiologic outcomes from a phase III randomized, controlled clinical trial designed to evaluate two doses of a compounded vaginal DHEA gel for the improvement of vaginal symptoms, dryness, or dyspareunia, in women with a history of breast or gynecologic cancer. The paper reporting the primary clinical endpoint related to symptom improvement, overall sexual function, and side effects is being published separately. Currently, in this paper, we evaluate the impact of vaginal DHEA on (1) circulating sex steroid concentrations (estradiol, estrone, free and total testosterone, and DHEA-S), (2) markers of bone formation (osteocalcin and bone alkaline phosphatase), and (3) vaginal cytology, specifically the maturation index and pH.
Methods
Population and design
These data were collected as part of a phase III randomized controlled trial evaluating two doses (3.25 and 6.5 mg/day) of vaginal DHEA compared to a plain moisturizer (PM). Eligibility criteria included women who reported problems with either vaginal dryness or dyspareunia, were postmenopausal, had a history of breast or gynecologic cancer, completed curative intent treatment, and had no evidence of disease. Participants could be on endocrine therapy (tamoxifen or aromatase inhibitors) but had to be on it for the past 2 months without planned changes. Women could not be using vaginal products other than water-based lubricants during intercourse, nor could they be using any oral or transdermal hormonal products (i.e., estrogen), including soy or compounded hormones. They could not have had prior or current radiation therapy to the pelvis nor have had any active vaginal infections. All women were asked to provide a blood sample at baseline and at 12 weeks. Additionally, a small subset of accruing sites volunteered to participate in vaginal cytology collection and vaginal pH measurement.
Intervention and control
The vaginal DHEA was developed by a compounding pharmacist under IND number 111454. The compounded base contained carbomer, squalane, vitamin E, and glycerin and was intended to act as a bioadhesive. DHEA was added to this base to provide 3.25-and 6.5-mg/day gels, while the PM arm consisted of the compounded bioadhesive base alone. Participants were instructed to use one prefilled syringe every night, after any sexual activity, if applicable, for the entire 12 weeks.
Physiologic endpoints
The evaluated physiologic endpoints included local effects on the vagina, specifically the vaginal maturation index (VMI) and vaginal pH; systemic effects on serum sex steroid hormone concentrations: estradiol, estrone, free and total testosterone, and dehydroepiandrosterone-sulfate (DHEA-S); and off-target effects, specifically biomarkers of bone formation: osteocalcin and bone alkaline phosphatase. These data were collected at baseline (before the start of the study treatment) and at the end of 12 weeks of treatment. Thirty milliliters (no additive) and 10 mL (EDTA) of whole blood were drawn and shipped on the same day with a cold pack to Mayo Clinic, Rochester, MN, where blood was processed into serum and plasma, respectively, and frozen at − 80°C until the assays were performed. All labs were performed by CLIA-approved Mayo Research Laboratories, using well-validated assays. Sex steroid hormone concentrations were measured to evaluate systemic absorption through vaginal tissue and explore mechanisms of action. Bone formation biomarkers were included as a surrogate measure to evaluate activity outside of the vagina, as increases in circulating estrogens improve biomarkers of bone turnover, both formation and resorption [22, 23] .
Vaginal cytology collection kits, consisting of pH papers (Baker pHIX) and a bottle of PreservCyt (Thin Prep), were provided to the subset of institutions participating in this collection. The vaginal cytology collection process included a vaginal exam, recording of the vaginal pH, and collection of vaginal cells. To collect pH, a pH indicator strip was held to the lateral wall of the mid portion of the vagina until fully moistened and color changed (15-30 s). The corresponding pH value was recorded on a data sheet included in the kit. While the speculum was still open, the rounded end of a spatula was used to gently scrape cells from the lateral wall of the middle portion of the vagina, opposite of the side used for pH sampling. The spatula was inserted into the Thin Prep container and gently stirred back and forth to dislodge the cells [24, 25] . The specimen was mailed to the Mayo Clinic for central pathology review. The cytological specimens were all read by the same pathologist who was blinded to the treatment assignment.
Statistical analysis
To evaluate the impact of vaginal DHEA on estradiol, estrone, free and total testosterone, DHEA-S, and markers of bone formation (osteocalcin and bone alkaline phosphatase), changes were calculated in each of the above biomarkers from baseline to 12 weeks. Two independent-sample t tests were performed, comparing each DHEA treatment arm in turn to the PM arm. Subset analyses were also performed, comparing biomarker concentrations between those on AIs and those not on AIs. Differences at baseline in sex steroid hormone concentrations between those on and not on AIs were also analyzed with a Wilcoxon or an equal variance t test, as appropriate.
To evaluate the impact of vaginal DHEA on the vaginal maturation index, due to the small numbers of women who participated in the vaginal cytology collection, we did not perform statistical analyses for VMI. Rather, we calculated the number and percent of women who had increases in the percentage of intermediate and superficial cells as opposed to parabasal cells. With regard to the pH, mean values were calculated from the recorded pH values and the change from baseline in these mean values was calculated. Descriptive data for pH are reported without performing statistical tests, due to the low number of participants in this portion of the study.
Results
Eighty institutions contributed blood specimens, representing 345 participants across the three arms who had evaluable specimens at baseline and after 12 weeks; eight institutions participated in collecting vaginal tissue/pH, representing 46 women who had evaluable data. The CONSORT diagram is shown in Fig. 1 . The demographic characteristics of those who contributed blood specimens for the systemic effects are identical to those reported in the manuscript about the primary outcome. A majority of women (97%) had a history of breast cancer, with 2% having a history of ovarian cancer and 1% with a history of endometrial cancer. The mean age was 57 years and 95% were white. A majority of the women were on AIs (56%) and had been on that therapy for a mean of almost 2 years. Demographic characteristics of those who contributed to vaginal cytology at both data points, baseline and 12 weeks, are listed in Table 1 .
Hormone and bone formation biomarker concentrations before the intervention and at 12 weeks and changes from baseline are shown in Table 2 . For the group as a whole, DHEA-S levels increased in a dose-dependent manner for those receiving DHEA and were significantly different from the PM group. The change from baseline to 12 weeks in estrone and testosterone (total and free) concentrations also significantly differed from that of PM for both doses of DHEA. For estradiol, only the 6.5-mg/day DHEA dose demonstrated a statistically significant increase compared with PM (p < 0.05). Bone formation biomarkers were not significantly changed, irrespective of arm (Table 2) .
When hormone concentrations were evaluated by whether women were on aromatase inhibitors, there were significant differences at baseline for estradiol and estrone, both being higher in those not on aromatase inhibitors (Table 3) . At baseline, there were significantly higher concentrations of DHEA-S, free testosterone, bone alkaline phosphatase, and osteocalcin in women who were on AIs; total testosterone concentrations were not significantly different. After 12 weeks on their assigned treatment, there were no significant increases in either estradiol or estrone concentrations among women taking AIs compared to PM, as opposed to significant increases in these concentrations in the women who were not taking an AI compared to PM (Table 4) .
Cytological effects are shown in Table 5 . No woman who received the PM experienced a decrease in pH to a level less than 5, while a small percent of women receiving either dose of vaginal DHEA experienced this level of decrease. In addition, more women on DHEA experienced cell maturation.
Discussion
Laboratory data from this clinical trial are consistent with previous studies that demonstrate vaginal tissue is a permeable membrane allowing for both systemic and local dosedependent effects. Systemic sex steroid hormone concentrations were small and similar to those described by Labrie [26] . Systemic absorption is best illustrated by the significant increases in systemic DHEA-S concentrations that were dose dependent.
The upper limit of normal for DHEA-S values per Mayo laboratories for a woman aged 50 and 60 is 200 and 157 mcg/ dL, respectively. Posttreatment values in both DHEA arms were significantly increased from baseline but still well within the normal range for postmenopausal women.
Postmenopausal estradiol values < 10 pg/mL by highsensitivity assay are considered to be low, and the posttreatment mean estradiol concentrations in this study remained < 5 pg/mL in both DHEA arms. Unexpectedly, however, the estradiol concentration changes from baseline were higher for the 3.25-mg/day DHEA group, with a larger standard deviation, than for the 6.5-mg/day DHEA group, even though the 3.25-mg/d DHEA group was not statistically significantly different from PM. This finding is not consistent with a dosedependent conversion of DHEA to systemic estradiol, and the reason for this is unknown. One possible explanation is that this data may reflect normal variations in estradiol levels within and between individuals. Estrone is a less potent estrogen than estradiol. The Mayo laboratory postmenopausal reference range for the estrone assay is 7-40 pg/mL. Mean estrone concentrations after using DHEA increased from baseline but remained in the lower half of the normal postmenopausal range (less than 15 pg/mL).
Estradiol or estrone concentrations did not change in women taking AIs and were not significantly different than those on PM. However, women taking AIs who received DHEA experienced the same level of improvement in their vaginal symptoms as those not on AIs [27] . This finding would support the hypothesis that vaginal DHEA is not working through estrogenic means.
Results of this laboratory analysis support the lack of offtarget effects of vaginal DHEA. Bone turnover biomarkers increase as women age, with postmenopausal values for bone alkaline phosphatase (BAP) being < 22 mcg/L and those for osteocalcin being between 9 and 42 ng/mL. Estrogen-based hormone replacement therapy at 12 weeks results in significant improvements in markers of bone formation, BAP, and osteocalcin [23] . BAP values for the women in this study were higher (worse) than usually seen after menopause, both at baseline and at 12 weeks, and were even higher at Asterisks and symbols indicating significant p values in the 3.25-mg DHEA column refer to 3.25 (mg/day) DHEA versus plain moisturizer. Asterisks and symbols indicating significant p values in the 6.5 mg DHEA column refer to 6.5 DHEA (mg/day) versus plain moisturizer. Data are given as mean ± SD ***p < 0.0001; **p < 0.001; *p < 0.01; §p < 0.05 baseline for women who were on AIs [28] . If vaginal DHEA was having systemic effects on bone, one would expect to see significant decreases for BAP and osteocalcin. This did not occur, with BAP increasing and osteocalcin decreasing minimally. This is consistent with a lack of off-target bone effects. One limitation of this analysis is that data were not collected about whether women were on bisphosphonates or any other medications that could impact bone health.
Vaginal DHEA did impact androgen concentrations, and the increases in androgen levels were consistent with the mild androgen side effects reported in the clinical outcomes [27] . Total testosterone ranges normally from 8 to 60 ng/dL in adult women. Total testosterone levels increased statistically significantly with both doses of DHEA, compared to the PM, with larger increases seen in the higher-dose arm. However, 12-week total testosterone values remained ≤ 25 ng/dL in all three arms. Total testosterone is a measure that includes bound testosterone which would generally not have physiologic activity. Free testosterone, which is not protein bound and is available for physiologic activity, ranges normally from 3 to 19 ng/ dL in women. In this study, mean free testosterone values were very low, < 1 ng/dL with a high sensitivity assay, both before and after the study intervention, irrespective of treatment arm.
Given the small but clear increase in systemic androgen concentrations, the safety of increased androgens is at issue with regard to hormone-dependent cancers such as breast cancer. Breast tissue does have enzymes required to convert DHEA into both androgens and estrogens, with a bias towards androgen formation in normal breast tissue. Data to date would suggest that the proliferation of both normal and cancerous tissue of the breast results from the balance between the stimulatory effects of estrogen and the inhibitory effects of androgens [29, 30] . There are two opposing perspectives about the safety of androgens, both informed by preclinical data which is not easy to extrapolate to the clinical setting due to complexities of cellular and tissue intracrinology [31] . In short, the current preclinical data favors a positive impact of androgens on both normal and malignant breast tissue [30, 32] .
In summary, these data support the lack of extra-vaginal physiologic effects, the absence of estradiol conversion in women on aromatase inhibitors, and improved vaginal cytological effects from DHEA. For women with severe vulvovaginal symptoms, DHEA may be helpful in providing cytological improvement which may result in more comprehensive symptom relief. Larger studies to evaluate risks versus benefits in cancer survivors, particularly those on AIs, are desired.
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